Actualités

They are way more than just GLP-1 stocks.

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering.

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens.

Novo Nordisk is playing catch-up in the GLP-1 race.

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.

Jeff Marks and Jim Cramer say Eli Lilly's GLP-1 stock rally has years left, backed by surging global demand.

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.

Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...

It's not much of a rivalry yet.

The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.

(Bloomberg) -- Stocks in Asia were poised to ease Thursday as investors digested gains in technology shares while watching for fresh signs of progress toward a deal to reopen the Strait of Hormuz.Most Read from BloombergIran Says Agreement on Hormuz Shipping Reached With OmanSpaceX’s AI Splurge Puts a Damper on First Earnings After IPOTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasit

Eli Lilly and Co (LLY) raises full-year 2026 guidance after Q2 revenue jumps 48%, driven by blockbuster incretin sales and strong international expansion.

Eli Lilly raised its revenue outlook after Mounjaro and Zepbound generated nearly two-thirds of quarterly sales.

Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.

Eli Lilly raised its 2026 sales forecast as its GLP-1 drugs outperformed expectations in Q2.

The S&P 500 climbed 0.6% on Wednesday, while SpaceX stock slumped more than 10% on its first quarterly report since going public

Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2026 revenue outlook, with strong demand for its Mounjaro and Zepbound weight-loss and diabetes...

Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.